Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of hematology"
DOI: 10.1002/ajh.26949
Abstract: Reverse transcription polymerase chain reaction (RT-PCR) for BCR::ABL1 is the most common and widely accepted method of measurable residual disease (MRD) assessment in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL); however, RT-PCR may not be an… read more here.
Keywords: ngs mrd; pcr bcr; pcr; bcr abl1 ... See more keywords
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01078-8
Abstract: The evaluation of measurable residual disease (MRD) in acute myeloid leukemia (AML) using comprehensive mutation analysis by next-generation sequencing (NGS) has been investigated in several studies. However controversial results exist regarding the detection of persisting… read more here.
Keywords: measurable residual; acute myeloid; residual disease; ngs mrd ... See more keywords
High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124305
Abstract: Background Studies from the chemoimmunotherapy (CIT) era and more recently with venetoclax have demonstrated the correlation between minimal residual disease (MRD) response measured by at least four-color flow cytometry (FC), and progression free (PFS) and… read more here.
Keywords: research; sensitivity; ngs mrd; research funding ... See more keywords
Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-129846
Abstract: Background: Measuring residual disease during the continuum of care is fundamental to oncology practice. In particular, minimal residual disease (MRD) assessments and trends over time can help inform clinical management, including change in treatment regimen… read more here.
Keywords: cell; disease; ngs mrd; research funding ... See more keywords
Integrating Next Generation Flow Cytometry and Next-Generation Sequencing for an Enhanced Detection of Measurable Residual Disease in Acute Myeloid Leukemia with Myelodysplasia-Related Gene Mutations
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-198602
Abstract: Background: The diagnosis of acute myeloid leukemia (AML) has evolved significantly with the last classifications of hematopoietic neoplasms (WHO and ICC 5th edition).1,2 A key update is the addition of a new AML group with… read more here.
Keywords: next generation; ngf mrd; mrd; ngs mrd ... See more keywords
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003738
Abstract: Next-generation sequencing (NGS) has been applied to measurable/minimal residual disease (MRD) monitoring after induction chemotherapy in patients with acute myeloid leukemia (AML), but the optimal time point for the test remains unclear. In this study,… read more here.
Keywords: time points; time; ngs mrd; time point ... See more keywords